B7-H3 CAR T cells for solid tumors in children and young adults
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of immune cell therapy called CAR T cells that target a protein called B7-H3 found on many solid tumors. It is for children and young adults whose cancer has come back or stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that has come back or is not responding to standard treatments.
- Your tumor must have a protein called B7-H3, which will be tested on a sample from a previous biopsy or surgery.
- You must be between 12 months and 30 years old.
- You need to be well enough to be up and about (performance status score of 50% or higher).
- You must have recovered from side effects of previous cancer treatments like chemotherapy or radiation before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune therapy using your own cells (called B7-H3 CAR T cells) to treat solid tumors that haven't responded to other treatments. It may help children and young adults with certain cancers that are hard to cure.
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
This trial tests a new type of immune therapy (CAR T cells) that targets a protein called B7-H3 found on some brain tumors. It is for children and young adults with certain brain or spinal cord tumors that have come back after standard treatment, and aims to see if the treatment is safe and effective.
This trial tests a new type of immune therapy called CAR T cells designed to find and attack a protein called B7-H3 on solid tumor cells. It's for children and young adults whose cancer came back or didn't respond to standard treatment.
This trial tests a new type of immunotherapy called B7H3 IL-7Ra CAR T-cells for children with DIPG, a tough-to-treat brain tumor. The treatment is given directly into the fluid around the brain using a special catheter, and the goal is to see if it's safe and if it can help fight the tumor.
Hear when a new Pediatric Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.